

Guido Cavaletti, MD

Research laboratory

School of Medicine and Surgery
University Milano-Bicocca
Via Cadore, 48 - 20900 Monza (MB)
Italy

Clinical office

Department of Neurology
S. Gerardo Hospital
Via Pergolesi, 33 – 20900 Monza (MB)
Italy

e-mail: guido.cavaletti@unimib.it
Tel.: +39 02 6448 8039 – Mobile + 39 335 1006664

Personal information	Date of birth: February, 27 th , 1959
	Place: Milan, Italy
Education	1984: MD (University of Milan "Statale")
	1989: Board in Neurology (University of Milan "Statale")
Professional experience	1990 - 1997 Department of Neurology, S. Gerardo Hospital Monza Assistant Neurologist
	1998 - Department of Neurology, S. Gerardo Hospital Monza Senior Consultant Neurologist
	2015 - Department of Neurology, S. Gerardo Hospital Monza Head, Neuroimmunology Unit
	2001 -2015 School of Medicine - University of Milan "Bicocca" Monza Associate Professor, Human Anatomy
	2015 - School of Medicine - University of Milan "Bicocca" Monza Professor, Human Anatomy
	2010- 2019 School of Medicine - University of Milan "Bicocca" Neuroscience PhD Program Director
	2001 - School of Medicine - University of Milan "Bicocca" Monza - Neurology Residency Program Faculty board member and Tutor
	2001 -2010 School of Medicine - University of Milan "Bicocca" International Translational Medicine PhD Program Tutor

2017- University of Milan "Bicocca"
Experimental Neurology Unit

Head

2014 -2019 Center of Neuroscience of Milan - University
of Milan "Bicocca"

Deputy Scientific Director

2015 -2018 University of Milan "Bicocca"
Schol of Medicine and Surgery

Deputy Director

2015 -2018 University of Milan "Bicocca"
School of Medicine and Surgery

Education Delegate

2018 - University of Milan "Bicocca"
University Academic Board member

2018 - University of Milan "Bicocca"
Vice Rector for Research

Main research activities

Basic research on the pathogenesis and treatment of peripheral neuropathies and neuroimmunological diseases.

He collaborated in developing several new *in vivo* and *in vitro* animal models of metabolic and toxic neuropathies (with particular reference to antineoplastic drug-induced neuropathies) to understand their pathogenesis and to test neuroprotective strategies.

He is currently involved also in experimental models of neuroimmunological diseases of the central and peripheral nervous system.

Besides light and electron microscopy, he has now a solid experience in the behavioral and neurophysiological evaluation of the central and peripheral nervous system in animals models. In order to enhance the quality of the data obtained from the animal models, he collaborates with top-level laboratories for the analytical determination of tissue drug concentrations and for skin biopsy examination.

Clinical research on chemotherapy-induced peripheral neurotoxicity and neuroimmunology.

Since 1990 he has been in charge of the neurological assessment during clinical trials devoted to the evaluation of neurological side-effects of chemotherapeutic agents and of the effect of neuroprotective agents. He developed the core of an Italian network of Oncologists/Hematologist and Neurologists with specific interest in chemotherapy-induced side effects (NETox). He is currently the leading member of the steering committee of the international EU/US CI-Perinoms study on the standardization of outcome measures in chemotherapy-induced peripheral neuropathies.

More recently he investigated on the role of autoimmunity in the development of clinical syndromes involving the central and peripheral nervous system. He is also involved in multiple sclerosis patients care and clinical trials and in the treatment of acute and chronic inflammatory neuropathies.

Diabetic Neuropathy

He is collaborating at the preclinical and clinical level in the study of this frequent and severe complication of diabetes, with a specific focus on neuroprotection and

transplantation procedures.

He gave lectures at meetings organized by the US National Cancer Institute, National Institute of Health, Food and Drug Administration, American Society for Clinical Oncology, American Academy of Neurology, European Neurology Society/European Federation of Neurological Societies (currently European Academy of Neurology), European Society for Clinical Oncology, and International Association for the Study of Pain.

In 2018 he proposed the Toxic Neuropathy Consortium within the Peripheral Nerve Society, and became its chair.

He received the 2020 Alan J. Gebhart – Peripheral Nerve Society Prize for Excellence in Peripheral Nerve Research.

Associations and Main Positions

He is member of the Italian Society of Neurology, of the World Federation of Neurology, of the Peripheral Nerve Society and past-President of the Italian Peripheral Nerve Society (ASNP).

2002 - 2005 European Federation of Neurological Societies CME Subcommittee: Member

2008 - Swiss League against Cancer: Expert Evaluator

2009 - European Commission: Expert Evaluator

2009 - Cancer Research UK: Expert Evaluator

2009 – 2015 European Synchrotron Radiation Facility, Biomedical Beam Scientific Board Member

2011- 2015 Peripheral Nerve Society: Board of Directors, Member

2012 - 2015 Italian Peripheral Nerve Society: President

2013 - 2017 SYRA3 European Union Cost Action: Managing Committee Member, President of Scientific Training Program Committee

2013 – Slovenian Research Council: Expert Evaluator

2014 – European Union COST Action: Expert Evaluator

2015 - Italian Peripheral Nerve Society: Board of Directors, Past-President

2018 - Toxic Neuropathy Consortium, Peripheral Nerve Society, Chair

2018 - Peripheral Nerve Society: Board of Directors, Member ex-officio

Other activities

Until 2019 Guido Cavaletti was associate editor Journal of the Peripheral Nervous System and is currently member of the editorial board of Experimental Neurology, Current Medicinal Chemistry, and Current Drug Safety.

He acts as reviewer for international peer-reviewed journals, including Nature, Neurology, Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Cancer Chemotherapy and Treatment, European Journal of Cancer, Oncology, Supportive Care in Cancer, European Journal of Neurology, Journal of Neuroimmunology, Neurobiology of Diseases, Neurotoxicology Research.

Consultant/Advisor: Metys Pharma, Shire Pharmaceuticals, Abbott, Helsinn Healthcare SA, Rottapharm-Biotech, Phosplatin, Periphagen. Pledpharma, Seattle Genetics, Acetylon Pharmaceuticals, Cavion Pharma, Eisai, Bristol Myers Squibb, Amgen, Fresenius, Medigene.

Publications

He authored more than 300 papers on international peer-reviewed journals (current Scopus h-index = 59, more than 12.000 citations)

See <https://pubmed.ncbi.nlm.nih.gov/?term=cavaletti+g&sort=date> for the complete list of published papers

Statement: I have already conducted clinical trials in ICH/GCP.

Monza February 8, 2021

A handwritten signature in black ink, reading "Guido Cavalletti". The signature is written in a cursive, flowing style.